Inventor · disambiguated record
Beatrice Diana Darimont
Also filed as: DARIMONT BEATRICE · DARIMONT BEATRICE DIANA
35 granted patents·19 pending applications·318 citations·filing 1999–2025
98Inventor score
Top patents by PatentIndex Score
54 records- 0198US11446387B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Sep 20, 2022·8 cites·14 claims
- 0298US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
- 0398US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
- 0498US11028179B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·16 cites·20 claims
- 0598US10913800B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·19 cites·27 claims
- 0698US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
- 0798US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
- 0898US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
- 0997US11707532B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 25, 2023·3 cites·14 claims
- 1097US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
- 1197US11555190B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·15 cites·17 claims
- 1297US11525137B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 13, 2022·13 cites·21 claims
- 1397US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
- 1497US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
- 1596US12049629B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 30, 2024·2 cites·22 claims
- 1696US11999955B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jun 4, 2024·2 cites·16 claims
- 1796US11912779B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Feb 27, 2024·6 cites·17 claims
- 1896US11834510B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 5, 2023·4 cites·20 claims
- 1996US11583591B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 21, 2023·2 cites·14 claims
- 2096US11554176B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·2 cites·16 claims
- 2195US12427202B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2023·Granted Sep 30, 2025·1 cites·9 claims
- 2295US12157774B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Dec 3, 2024·1 cites·5 claims
- 2395US12071485B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Aug 27, 2024·2 cites·13 claims
- 2495US10800848B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·7 cites·16 claims
- 2594US12104156B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Oct 1, 2024·1 cites·16 claims
- 2694US11872287B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jan 16, 2024·1 cites·17 claims
- 2789US12359202B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jul 15, 2025·1 cites·21 claims
- 2889US12071621B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2023·Granted Aug 27, 2024·1 cites·21 claims
- 2989US2024287522A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3089US2025340880A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3188US12486328B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Granted Dec 2, 2025·0 cites·19 claims
- 3288US2024400707A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3387US2025381285A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3486US12263224B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
- 3585US2023047754A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3684US2025381286A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3783US2024228646A9Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3881US11712478B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 1, 2023·0 cites·13 claims
- 3979US12351637B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jul 8, 2025·0 cites·15 claims
- 4079US12234290B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 25, 2025·0 cites·23 claims
- 4178US2025195676A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4278US2025171544A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4375US2020123261A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 4469US2017281795A1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES LLC·Filed 2017·Application pending·0 cites
- 4569US2025170260A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4668US2025121085A1Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4767US2022033434A1Androgen receptor nucleic acids and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4857US12497615B2Nucleic acid compositions and methods of multi-exon skippingAVIDITY BIOSCIENCES INC·Filed 2020·Granted Dec 16, 2025·0 cites·15 claims
- 4957US2020282074A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 5055US2023330246A1Compositions and methods of treating pompe diseaseAVIDITY BIOSCIENCES INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Beatrice Diana Darimont files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →